

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 2, 1974

SUBJECT INDEX

- Abstinence syndrome
 alcohol withdrawal and motor control, 791
- Acclimation
 Δ^9 -THC and wheel running, 435
- Acoustic startle response
 N-N-dimethyltryptamine, 827
 5-HT involvement, 161
- ACTH₁₋₂₄
 anxiety, attention and memory, human, 663
- ACTH₄₋₁₀
 anxiety, attention and memory, human, 663
- Activity
 d-amphetamine and strain differences, 803
 cycloheximide, 753
 locomotion, striatal lesions and amphetamine, 697
 6-OHDA sympathectomy, 381
 pargyline, 753
 wheel running and Δ^9 -THC, 435
- Adenosine
 2,6 diaminopurine and memory, 9
 2,6 diaminopurine and RNA synthesis, 9
- Adrenalectomy
 tetrabenazine, ovariectomy and mating, 685
- Affect
 marijuana, users and non-users, 367
- Aggregation
 d-amphetamine and activity, 803
- Aggression
 aggressive rats and acoustic startle conditioning, 729
 AMT and PCPA effects, 123
 brain 5-HT and raphe lesions, 277
 bulbectomy, brain ACh and mouse-killing, 703
 intracerebral carbachol and rage, 141
 isolation and sodium nitrite, 267
 mouse killing rats and limbic RNA, 729
 6-OHDA and pargyline, 651
 shock induced, mescaline effect, 777
- Alcohol
 concentration and intake, 589
 conflict behavior, goldfish, 545
 dependence, technique to produce, 831
 dependency and motor control, 791
 ethanol vs sherry, avoidance learning, 317
 lighting, pinealectomy and melanotonin, 459
 morphine suppression of drinking, 409
 polydipsia and alcohol overdrinking, 791
 preference, neural tolerance, 549
 prolonged consumption and retrograde amnesia, 63
 schedule-induced polydipsia, saccharin, 835
 self-administration, water deprivation, 447
 state-dependent learning, non-alcoholics, 293
 stress and self selection, 27
 withdrawal and dependence, 523
 withdrawal, operant behavior, 847
- d-Aldosterone
 eating and salt intake, 19
- Amino acid
 dietary deficiency and food aversion, 481
- Amnesia
 cycloheximide, pretraining, 585
 cycloheximide, and recovery, 173
 ECS and scopolamine, 443
 metrazol and brain norepinephrine, 261
 recovery, pretest monoamine oxidase inhibitors, 375
- Amphetamine
 isomers, locomotor and stereotyped behavior, 115
 locomotor activity, striatal lesions, 697
- d-Amphetamine
 attention and memory, hooded vs albino rat, 557
 discriminative stimulus properties, 669
 epinephrine and avoidance learning, 427
 food vs brain stimulation and FR responding, 193
 handling and avoidance learning, 439
 illumination and aggregation, activity, 803
 intraventricular infusion and activity, 79
 long-term administration, motor activity and stereotypy, 249
 response sequence acquisition, 741
 taste aversion, 325
 visual discrimination learning, 557
 strain and locomotor activity, 803
- l-Amphetamine
 discriminative stimulus properties, 669
 taste aversion, 325
- Amphetamine sulfate
 arousal and visually evoked potentials, 187
- AMPT
 brain amine levels and competitive behavior, 55
 cocaine self-administration, 563
- AMT
 inter-species attack, 123
 shock induced aggression, 123
- Amygdala
 norepinephrine and eating, 421
 pO₂ psychotropic drugs, 763
- Anemia
 sleep deprivation, PCPA enhancement, 817
- Anesthesia
 barbiturate, thalamic discharge patterns, 339
 rat head-holder, 127
- Angiotensin II
 drinking, sar¹-Ala⁸ angiotensin II, 401
 L-DOPA, 5HTP and behavior, 105
 intracranial infusion and drinking, 509
 LH injection and drinking, 235
 preoptic injection and drinking, 235
 preoptic injection and drinking, LH lesion, 515
 septal injection and drinking, 235, 597
- Anorexia

- d- and l-amphetamine taste aversion, 325
- glucocorticoid injection, 19
- Anticonvulsant activity
 - Δ^8 - and Δ^9 -THC, 227
- Anxiety
 - ACTH₄₋₁₀, human, 663
- Apomorphine
 - locomotion and BOL-148, 263
 - locomotion and methysergide, 263
 - locomotion and p-chloroamphetamine, 263
 - self-administration, pimoziide disruption, 387
 - sexual behavior, male rat, 257
 - striatal lesions, 181
- Apparatus
 - anesthesia head-holder, rat, 127
 - microinjector for autoradiography, 111
 - watertight fluid swivel, 2 channel, 131
- Approach learning
 - interanimal brain extract alteration, 209
- Arousal
 - pharmacological, and visually evoked potentials, 187
- Attention
 - ACTH₄₋₁₀, human, 663
 - d-amphetamine, hooded vs albino rat, 557
- Atropine
 - hippocampus, hypothalamic carbachol rage, 285
 - morphine and LSD, stimulus effects, 361
 - tissue disposition, 843
- Atropine methylnitrate
 - autonomic blockade and heart rate conditioning, 493
 - neostigmine and conditioned avoidance, 67
 - physostigmine and conditioned avoidance, 67
- Atropine sulfate
 - aversive threshold, rat, 631
 - hippocampal lesions and alternation, 297
- Autonomic blockade
 - classical heart rate conditioning, 493
- Autoradiography
 - microinjection apparatus, 111
- Aversive threshold
 - cholinergic activity modulation, 631
- Avoidance behavior
 - raphe lesions, 215
 - striatal 6-OHDA, 97
- Avoidance learning
 - d-amphetamine and handling interaction, 439
 - effects of ethanol and sherry, 317
 - epinephrine and d-amphetamine, 427
 - epinephrine and scopolamine, 427
- Avoidance training
 - uridine RNA incorporation, 579
- Barbital
 - tolerance and drinking, 431
- Barbiturate anesthesia
 - nucleus reticularis thalami discharge pattern, 339
- Behavioral contrast
 - cocaine intake, extinction and punishment, 199
- Behavioral suppression
 - M56, diazepam and caffeine, 619
- Behavioral tolerance
 - DFP and cholinergic agents, 45
 - Δ^9 -THC and prior training, 243
- Beta-adrenergic drinking
 - Sar¹-Ala⁸ angiotensin II, 401
- Bioassay
 - behavior, interanimal transfer, 209
- Blood sugar
 - insulin and lever pressing, 35
- BOL-148
 - apomorphine induced locomotion, 263

Brain

- amygdala, 421, 763
- caudate, 141, 509, 639
- central grey, 141
- cingulate cortex, 573
- corpus striatum, 97
- hippocampus, 1, 285, 297, 421, 573, 715
- hypothalamus, 141, 193, 283, 393, 421, 493
- injected drug spread, 715
- lateral geniculate, 493
- lateral hypothalamus (LH), 235, 509, 515, 531, 735, 811
- mesencephalic reticular formation, 141
- nucleus reticularis thalami, 339
- olfactory bulb, 347, 703
- pons, 355
- pontine reticular formation, 763
- preoptic region, 235, 455, 509, 515
- raphe nuclei, 215, 277, 675
- red nucleus, 141
- septum, 141, 235, 493, 509, 597
- striatum, 181, 697
- substantia nigra, 87
- thalamus, 141
- ventromedial hypothalamus (VMH), 223
- visual cortex, 573
- Brain ACh
 - bulbectomy and mouse-killing, 703
- Brain acetylcholinesterase
 - puromycin inhibition, 271
- Brain amines
 - AMPT and competitive behavior, 55
 - DOPA and competitive behavior, 55
 - FLA-63 and competitive behavior, 55
 - PCPA and competitive behavior, 55
 - tryptophan and competitive behavior, 55
- Brain corticosterone
 - olfactory bulb section and conditioning, 347
- Brain 5-HT
 - raphe lesions, 215
- Brain noradrenaline
 - olfactory bulb section and conditioning, 347
- Brain stimulation
 - amphetamine and FR responding, 193
- Brevital
 - nucleus reticularis thalami discharge patterns, 339
- Bulbectomy
 - brain ACh and mouse-killing, 703
- Caffeine
 - MSG and behavioral suppression, 619
- Cannabichromene
 - conditioned taste aversion, 725
- Cannabidiol
 - conditioned taste aversion, 725
- Cannabigerol
 - conditioned taste aversion, 725
- Carbachol
 - brain injection and drinking, 235
 - hypothalamic rage and hippocampal drugs, 285
 - intracerebral injection and rage, 141
 - LH infusion, EEG and heart rate, 531
- Catron
 - amnesia reversal, pretest injection, 375
- Caudate nucleus
 - carbachol and rage, 141
 - 6-OHDA injection, avoidance and ingestive behavior, 639
 - renin- and angiotensin-induced drinking, 509
- Central grey
 - carbachol and rage, 141
- Chemical lesions
 - 6-OHDA injection, 393
- Chlordiazepoxide

- response force in extinction, 155
- schedule-dependent response effects, 465
- p-Chloroamphetamine
 - apomorphine induced locomotion, 263
 - PKU learning deficit, 5HT, 783
- Chlorpromazine
 - response force in extinction, 155
 - response sequence acquisition, 741
 - tonic immobility, 119
- Cingulate cortex
 - leucine incorporation and learning, 573
- Cocaine
 - extinction and self-administration, 199
 - punishment and self-administration, 199
 - self-administration, aminergic influences, 563
- Competitive behavior
 - brain amine levels, 55
- Conditioned avoidance
 - neostigmine, 67
 - physostigmine, 67
- Conditioned taste aversion
 - cannabichromene, 725
 - cannabidiol, 725
 - cannabigerol, 725
 - morphine withdrawal, 613
 - Δ^8 - and Δ^9 -THC, 725
- Conditioning
 - acoustic startle, aggressive rats, 729
- Conflict behavior
 - ethanol, goldfish, 545
 - phenobarbital, goldfish, 545
 - shock stress and alcohol self selection, 27
- Corpus striatum
 - 6-OHDA and avoidance behavior, 97
- Corticosterone
 - eating and salt intake, 19
- Cutaneous sensitivity
 - marijuana, users and non-users, 367
- Cycloheximide
 - amnesia, 173, 375
 - locomotor activity vs memory, 753
 - preoptic infusion and maternal behavior, 455
 - pretraining and amnesia, 585
- Cyclophosphamide
 - sodium appetite and hyponatremia, 627
- Cyproheptadine
 - morphine and LSD, stimulus effects, 361
- Cyproterone acetate
 - growth and feeding in rats, 309
- Depakine
 - photically evoked after-discharge bursting, 839
- Dependence
 - alcohol, technique to produce, 831
 - alcohol, withdrawal, 835
 - alcohol withdrawal and self-selection, 523
 - morphine, 613
- Desmethylinipramine
 - intraventricular amphetamine and activity, 79
 - intraventricular norepinephrine and activity, 79
- Dexamethasone
 - eating and salt intake, 19
- DFP
 - behavioral tolerance and cholinergic agents, 45
- 5,6-DHT
 - behavior and brain amines, 769
- 5,7-DHT
 - behavior and brain amines, 769
- 6,7-DHT
 - behavior and brain amines, 769
- Diabetes
 - rats, VMH insulin injection and eating, 223
- 2,6 Diaminopurine
 - long term memory, adenosine, 9
 - RNA synthesis, adenosine, 9
- Diazepam
 - MSG and behavioral suppression, 619
 - schedule-dependent response effects, 465
- Diazoxide
 - beta-adrenergic dipsogenesis, 401
- Dibutyryl cyclic AMP
 - 6-OHDA sympathectomy, 719
- Dicumarol
 - sleep deprivation amnesia, PCPA enhancement, 817
- Diet
 - salt restriction, plasma renin, human, 757
- Diethyldithiocarbamate
 - amnesia, 375
- Dilantin
 - photically evoked after-discharge bursting, 839
- N-N-dimethyltryptamine
 - startle reflex, 827
- Discrimination learning
 - tetraethyl lead, 473
- Discriminative stimulus
 - d-amphetamine and related compounds, 669
 - morphine and LSD comparison, 361
- Dissociation
 - alcohol and learning, humans, 293
- Disulfiram
 - LH self-stimulation, 735
- DMT
 - brain amine levels and competitive behavior, 55
- DOCA
 - eating and salt intake, 19
 - 6-OHDA and cardiovascular changes, 537
- DOPA
 - brain amine levels and competitive behavior, 55
 - growth hormone-RIH potentiation, 693
- L-DOPA
 - locomotor and stereotyped behavior, 115
 - pontile lesions and grooming, 355
 - sexual behavior, male rat, 257
 - TRH, angiotensin II, MIF and behavior, 105
 - tryptamine derivatives and behavior, 769
 - tryptamine derivatives and brain amines, 769
- Dopamine
 - hippocampus, hypothalamic carbachol rage, 285
- Drinking
 - hypothalamic 6-OHDA injection, 393
 - intracranial renin and angiotensin, 509
 - intraventricular 6-OHDA, 651
 - LH norepinephrine, photoperiod, 811
 - preoptic angiotensin and LH lesion, 515
 - quinterenol dipsogenesis, 413
 - salbutamol dipsogenesis, 413
 - Sar¹-Ala⁸ angiotensin II, renin dipsogenesis, 401
 - Sar¹-Ala⁸ angiotensin II, angiotensin dipsogenesis, 401
 - septal angiotensin II, 597
- Drug
 - ACTH₁₋₂₄, 663
 - ACTH₄₋₁₀, 663
 - adenosine, 9
 - alcohol, 63, 293, 317, 409, 523, 545, 549, 589, 791
 - alpha-methyl paratyrosine AMPT, 563
 - amphetamine, 115, 697
 - d-amphetamine, 79, 193, 249, 325, 427, 439, 557, 669, 741, 803
 - l-amphetamine, 325, 669
 - amphetamine sulfate, 187
 - angiotensin II, 105, 235, 401, 509, 515, 597
 - apomorphine, 181, 257, 263, 387
 - atropine, 285, 361, 843
 - atropine methylnitrate, 67, 493
 - atropine sulfate, 297, 631

- barbital, 431
- bis-(4-methyl-1-homopiperazinyl-thiocarbonyl) disulfide (FLA-63), 55
- BOL-148, 263
- brevital, 339
- caffeine, 619
- cannabichromene, 725
- cannibiol, 725
- cannabigerol, 725
- carbachol, 141, 235, 285, 531
- catron, 375
- chlordiazepoxide, 155, 465
- p-chloroamphetamine, 263, 783
- chlorpromazine, 119, 155, 741
- cocaine, 199, 563
- cycloheximide, 173, 375, 455, 585, 753
- cyclophosphamide, 627
- cyproheptadine, 361
- cyproterone acetate, 309
- depakine, 839
- desmethylinipramine, 79
- dexamethasone, 19
- 2,6-diaminopurine, 9
- diazepam, 465, 619
- diazoxide, 401
- dibutyl cyclic AMP, 719
- diethyldithiocarbamate, 375
- dihydroxyphenylalanine (L-DOPA), 55, 115, 257, 355
- 5,6-dihydroxytryptamine (5,6-DHT), 769
- 5,7-dihydroxytryptamine (5,7-DHT), 769
- 6,7-dihydroxytryptamine (6,7-DHT), 769
- diisopropylfluorophosphate (DFP), 45
- dilantin, 839
- N-N-dimethyltryptamine, 827
- 3,α-dimethyltyrosine-methylester HCl (DMT), 55
- disulfiram, 735
- L-DOPA, 105, 693
- dopamine, 285
- ephedrine, 669
- epinephrine, 427
- eserine sulfate, 631
- ethanol, see alcohol
- 4-ethyl-2,5-dimethoxyamphetamine, 669
- gangliron, 1
- haloperidol, 257, 597, 763
- 6-hydroxydopamine (6-OHDA), 79, 87, 381, 393, 639, 651, 719
- 5-hydroxytryptamine (5-HT), 137
- 5-hydroxytryptophan (5-HTP), 105, 137, 355, 693
- (-) hyoscyamine, 67
- insulin, 35, 223
- isoprenaline, 285
- isoproterenol, 401
- loxapine, 747
- lysergic acid diethylamide (LSD), 263, 361, 675
- marijuana, 367
- meprobamate, 465
- mescaline, 669, 777
- metamyl, 1
- methamphetamine, 503, 851
- 4-methoxyamphetamine, 669
- methylatropine bromide, 297
- 4-methyl-2,5-dimethoxyamphetamine, 669
- methylmercury chloride, 709
- methylphenidate, 669
- α-methyl-tyrosine (AMT), 123
- α-methyl-p-tyrosine (AMPT), 55
- methysergide, 263, 361
- metrazol, 261, 839
- monosodium glutamate, 619
- morphine, 215, 361, 409, 613
- naloxone, 361
- neostigmine, 67
- nicotine, 285
- nitrazepam, 763
- noradrenaline, 285
- norephedrine, 669
- norepinephrine, 79, 235, 421, 531, 719, 811
- oxazepam, 465
- oxotremorine, 417, 693
- dl-para-chlorophenylalanine (PCPA), 55, 123, 161, 355, 817
- pargyline, 375, 563, 651, 753
- penicillin, 1
- pentobarbital, 763
- phenobarbital, 465, 545
- phenoxybenzamine, 563
- phenolamine, 493, 563, 735
- phenylephrine, 285
- physostigmine, 67, 187
- pilocarpine, 187, 631
- pimozide, 387
- prolyl-leucyl-glycine-amide, 417
- propranolol, 493
- puromycin, 271
- quinterenol, 401, 413
- reserpine, 161, 563
- R04-4602, 257
- salbutamol, 413
- Sar¹, Ala³, Ile⁸-angiotensin I, 597
- Sar¹-Ala⁸-angiotensin II, 401
- scopolamine, 297, 427, 443, 631
- scotophobin, 147
- seryl-trihydroxybenzyl-hydrazine, 355
- sodium nitrite, 267
- sodium pentobarbital, 331, 603
- spiroperidol, 181, 735
- tetrabenazine, 685
- tetraethyl lead, 473
- Δ⁸-tetrahydrocannabinol (Δ⁸-THC), 227, 607, 725
- Δ⁹-tetrahydrocannabinol (Δ⁹-THC), 227, 243, 435, 487, 725
- tridione, 839
- tryptophan, 55
- uridine, 579
- Drug spread
 - intrahippocampal injection, 715
- Eating
 - glucocorticoid injection, 19
 - hypothalamic 6-OHDA injection, 393
 - intraventricular 6-OHDA, 651
 - LH norepinephrine, photoperiod, 811
- ECS
 - amnesia and scopolamine, 443
- EEG
 - LH carbachol infusion, 531
 - LH epinephrine infusion, 531
- Emotionality
 - tetraethyl lead, 473
- Ephedrine
 - discriminative stimulus properties, 669
- Epinephrine
 - d-amphetamine and avoidance learning, 427
 - scopolamine and avoidance learning, 427
- Eserine sulfate
 - aversive threshold, rat, 631
- Ethanol
 - see alcohol
- 4-Ethyl-2,5-dimethoxyamphetamine
 - discriminative stimulus properties, 669
- Extinction
 - chlordiazepoxide and response force, 155
 - chlorpromazine and response force, 155
 - cocaine self-administration, 199

- pentobarbital withdrawal, 331
- Δ^9 -THC, 487
- Facilitation
 - LSD, acoustic startle response, 675
- Fixed ratio schedule
 - alcohol concentration and intake, 589
- FLA-63
 - brain amine levels and competitive behavior, 55
- Flower pot technique
 - REM sleep deprivation, 553
- 9 alpha fluorocortisone
 - eating and salt intake, 19
- Food
 - reinforcement, amphetamine and FR responding, 193
- Food deprivation
 - alcohol concentration and intake, 589
- Food intake
 - cyproterone acetate and androgens, 309
 - VMH insulin injection, normal and diabetic rats, 223
- Fucose
 - stimulation and glycoproteins, 73
- Gangleron
 - hippocampal seizure after discharge, 1
- Globus pallidum
 - 6-OHDA injection, avoidance and ingestive behavior, 639
- Glycoproteins
 - environmental stimulation and fucose incorporation, 73
- Grooming behavior
 - pontile lesions, serotonergic system, 355
- Group stability
 - methamphetamine, 851
- Growth
 - cyproterone acetate and androgens, 309
- Growth hormone-RIH
 - DOPA potentiation, 693
- Habituation
 - LSD, acoustic startle response, 675
- Haloperidol
 - amygdala pO_2 , REM sleep, 763
 - antagonism of angiotensin II drinking, 597
 - pontine reticular formation pO_2 , REM sleep, 763
 - sexual behavior, male rat, 257
- Handling
 - d-amphetamine and avoidance learning, 439
- Head-holder
 - rat anesthesia, 127
- Heart rate
 - autonomic blockade and conditioning, 493
 - intraventricular 6-OHDA, 651
 - LH carbachol infusion, 531
 - LH norepinephrine infusion, 531
 - 6-OHDA and conditioning, 537
 - 6-OHDA and DOCA, 537
- Hippocampus
 - drug injection and hypothalamic carbachol rage, 285
 - lesions, atropine and spatial alternation, 297
 - lesions, scopolamine spatial alternation, 297
 - leucine incorporation and learning, 573
 - norepinephrine and eating, 421
 - ^3H -orotic acid injection, spread, 715
 - seizure afterdischarge, gangleron, 1
 - seizure afterdischarge, metamyzil, 1
- Hormone
 - d-Aldosterone, 19
 - 9 alpha fluorocortisone, 19
 - corticosterone, 19
 - DOCA, 19, 537
 - growth hormone release inhibiting hormone (GH RIH), 693
 - melatonin, 459
 - MSH release-inhibiting factor (MIF), 105
 - progesterone, 685
 - prostaglandin, E_1 , 421
 - renin, 401, 509
 - testosterone propionate, 309
 - thyrotropin releasing hormone (TRH), 105
- 5-HT
 - acoustic startle reaction, 161
 - subcutaneous vs i.p. injection and locomotion, 137
 - tryptamine derivatives and behavior, 769
 - tryptamine derivatives and brain amines, 769
- 5-HTP
 - growth hormone-RIH effect, 693
 - pontile lesions and grooming, 355
 - subcutaneous vs i.p. injection and locomotion, 137
 - TRH, angiotensin II, MIF and behavior, 105
- Human
 - alcohol, state-dependent learning, 293
 - Δ^8 -THC and tonal preference, 607
- (-) Hyoscyamine
 - neostigmine and conditioned avoidance, 67
 - physostigmine and conditioned avoidance, 67
- Hyponatremia
 - cyclophosphamide, 627
- Hypothalamus
 - carbachol and rage, 141
 - carbachol rage and hippocampal drugs, 285
 - conditioned stimulus and heart rate, 493
 - norepinephrine and eating, 421
 - 6-OHDA injection, eating and drinking, 393
 - 6-OHDA injection, food motivated behavior, 393
 - 6-OHDA lesions, 393
 - stimulation, amphetamine and FR responding, 193
- Illumination
 - d-amphetamine and activity, 803
- Insulin
 - food reinforced lever pressing, 35
 - VMH injection normal and diabetic rats, 223
- Intragastric infusion
 - rat, long term, 131
- Isoprenaline
 - hippocampus, hypothalamic carbachol rage, 285
- Isoproterenol
 - beta-adrenergic dipsogenesis, 401
- Lateral geniculate
 - unconditioned stimulus and heart rate, 493
- Lateral ventricle
 - renin- and angiotensin-induced drinking, 509
- Learned tolerance
 - Δ^9 -THC and prior training, 243
- Learning
 - d-amphetamine and response sequences, 741
 - brain extract alteration, 209
 - chlorpromazine and response sequences, 741
 - leucine incorporation in brain cells, 573
 - mercury toxicity, 709
 - 6-OHDA lesions of nigro-neostriatal projection, 87
 - Δ^9 -THC, 487
 - uridine incorporation in RNA, 579
- Leucine
 - incorporation in brain cells, learning, 573
- LH
 - angiotensin II and drinking, 235
 - carbachol, EEG and heart rate, 531
 - epinephrine, EEG and heart rate, 531
 - lesion, preoptic angiotensin and drinking, 515
 - norepinephrine and drinking, 235

- norepinephrine injection, feeding and photoperiod, 811
- renin- and angiotensin-induced drinking, 509
- self-stimulation, disulfiram, 735
- self-stimulation, phentolamine, 735
- self-stimulation, spiroperidol, 735

Limbic system

- RNA content in aggressive rat, 729

Locomotor behavior

- amphetamine isomers, 115
- apomorphine and BOL -148, 263
- apomorphine and methysergide, 263
- apomorphine and p-chloroamphetamine, 263
- 5-HT and 5-HTP injection, 137

Loxapine

- sleep-wakefulness cycle, rat, 747

LSD

- apomorphine induced locomotion, 263
- habituation and sensitization, startle response, 675
- stimulus effects, morphine comparison, 361

Marijuana

- users and non-users, affect, 367
- users and non-users, cutaneous sensitivity, 367

Maternal behavior

- preoptic cycloheximide infusion, 455

Melatonin

- alcohol consumption, 459

Memory

- ACTH₄₋₁₀ human, 663
- d-amphetamine, hooded vs albino rat, 557
- cycloheximide, 753
- cycloheximide and amnesia, 173
- 2,6 diaminopurine and adenosine, 9
- pargyline, 753
- pretraining and cycloheximide amnesia, 585

Memory retrieval

- sodium pentobarbital amnesia, 603

Meprobamate

- schedule-dependent response effects, 465

Mercury

- learning deficits, 709
- brain content and learning, 709

Mescaline

- discriminative stimulus properties, 669
- shock-induced aggression, 777

Mesencephalic reticular formation

- carbachol and rage, 141

Metamyzil

- hippocampal seizure afterdischarge, 1

Methamphetamine

- chronic intoxication, tolerance, 503
- group stability, 851
- social responses, 851

Method

- alcohol dependence production, 831
- intragastric catheterisation, rat, 131
- long term infusion technique, 131

4-Methoxyamphetamine

- discriminative stimulus properties, 669

Methylatropine bromide

- hippocampal lesions and alternation, 297

4-Methyl-2,5-dimethoxyamphetamine

- discriminative stimulus properties, 669

Methylphenidate

- discriminative stimulus properties, 669

Methysergide

- apomorphine induced locomotion, 263
- morphine and LSD, stimulus effects, 361

Metrazol

- brain norepinephrine and amnesia, 261
- photically evoked after discharge, 839

Microinjection

- stereotaxic apparatus, 111

Monosodium l-glutamate (MSG)

- behavioral suppression, 619

Morphine

- alcohol drinking, 409
- analgesia, raphe lesions, 215
- stimulus effects, LSD comparison, 361
- withdrawal and saccharin aversion, 613

Motor activity

- d-amphetamine long-term administration, 249

Motor control

- alcohol dependency, 791

MSH release-inhibiting factor

- L-DOPA, 5HTP and behavior, 105

Muscarinic receptors

- DFP, cholinergic agents and behavioral tolerance, 45

Naloxone

- morphine and LSD, stimulus effects, 361

Neostigmine

- conditioned avoidance, 67

Neural tolerance

- alcohol, 549

Nicotine

- hippocampus, hypothalamic carbachol rage, 285

Nicotinic receptors

- DFP, cholinergic agents and behavioral tolerance, 45

Nigro-neostriatal projection

- 6-OHDA lesions and instrumental responding, 87

Nitrazepam

- amygdala pO₂, REM sleep, 763
- pontine reticular formation pO₂, REM sleep, 763

Nitrites

- isolation-induced aggression, 267

Noradrenaline

- hippocampus, hypothalamic carbachol rage, 285

Norephedrine

- discriminative stimulus properties, 669

Norepinephrine

- intracranial injection and eating, 421
- intraventricular infusion and activity, 79
- LH infusion, EEG and heart rate, 531
- LH injection and drinking, 235
- LH injection, feeding and photoperiod, 811
- metrazol and amnesia, 261
- 6-OHDA sympathectomy, 719
- preoptic injection and drinking, 235
- septal injection and drinking, 235

Nucleus reticularis thalami

- barbituate anesthesia and discharge patterns, 339

6-OHDA

- brain dopamine, 651
- brain norepinephrine, 651
- brain serotonin, 651
- cardiovascular changes and conditioning, 537
- cardiovascular changes and DOCA, 537
- catecholamine pathways, avoidance and ingestive behavior, 639
- chemical lesions, hypothalamus, 393
- hypothalamus, eating and drinking, 393
- intraventricular amphetamine and activity, 79
- intraventricular norepinephrine and activity, 79
- intraventricular injection, aggression, 651
- intraventricular injection, drinking, 651
- intraventricular injection, eating, 651
- intraventricular injection, heart rate, 651
- intraventricular injection, sleep, 651
- lesions, nigro-striatal projection and instrumental responding

- striatal injection and avoidance, 97
- sympathectomy, dibutyl cyclic AMP, 719
- sympathectomy, norepinephrine, 719
- sympathectomy, normal & hypertensive rat, 381
- Olfaction
 - aversion to amino acid deficient diet, 481
- Olfactory bulb
 - removal, brain ACh and mouse-killing, 703
 - section, brain noradrenaline, corticosterone and conditioning, 347
- Operant behavior
 - alcohol withdrawal, 847
 - insulin and food reinforced lever pressing, 35
 - Δ^9 -THC, acquisition and extinction, 487
- Ovariectomy
 - adrenalectomy, tetrabenazine and mating, 685
- Oxazepam
 - schedule-dependent response effects, 465
- Oxotremorine
 - antagonism by prolyl-leucyl-glycine-amide, 417
 - growth hormone-RIH effect, 693
- Paradoxical sleep
 - loxapine, 747
- Pargyline
 - amnesia reversal, pretest injection, 375
 - cocaine self-administration, 563
 - locomotor activity vs memory, 753
- Passive avoidance
 - cycloheximide and amnesia, 173
 - pretraining and cycloheximide amnesia, 585
- PCPA
 - acoustic startle and 5-HT, 161
 - brain amine levels and competitive behavior, 55
 - inter-species attack, 123
 - pontile lesions and grooming, 355
 - shock induced aggression, 123
 - sleep deprivation amnesia enhancement, 817
- Penicillin
 - hippocampal seizures, ganglerson, 1
 - hippocampal seizures, metamytil, 1
- Pentobarbital
 - amygdala, pO_2 REM sleep, 763
 - pontine reticular formation, REM sleep, 763
- Phenobarbital
 - conflict behavior, goldfish, 545
 - schedule-dependent response effects, 465
- Phenoxybenzamine
 - cocaine self-administration, 563
- Phentolamine
 - autonomic blockade and heart rate conditioning, 493
 - cocaine self-administration, 563
- Phentolamine mesylate
 - LH self-stimulation, 735
- Phenylephrine
 - hippocampus, hypothalamic carbachol rage, 285
- Phenylindanedione
 - sleep deprivation amnesia, PCPA enhancement, 817
- Phenylketonuria
 - p-chloroamphetamine and PKU learning, 783
- Photoperiod
 - LH norepinephrine, feeding, 811
 - lighting, alcohol consumption, 459
- Physostigmine
 - arousal and visually evoked potentials, 187
 - conditioned avoidance, 67
- Pilocarpine
 - arousal and visually evoked potentials, 187
 - aversive threshold, rat, 631
- Pimozide
 - apomorphine self-administration disruption, 387
- Pinelectomy
 - alcohol consumption, 459
- Polydipsia
 - alcohol, schedule-induced, saccharin, 835
 - chronic alcohol overdrinking, 791
 - schedule-induced, alcohol, 835
- Pons
 - lesions and grooming behavior, cat, 355
- Pontine reticular formation
 - 6-OHDA injection, avoidance and ingestive behavior, 639
 - pO_2 psychotropic drugs, 763
- Preoptic area
 - angiotensin and drinking, LH lesion, 515
 - angiotensin II and drinking, 235
 - cycloheximide and maternal behavior, 455
 - norepinephrine and drinking, 235
 - renin- and angiotensin-induced drinking, 509
- Progesterone
 - ovariectomy, adrenalectomy tetrabenazine and mating, 685
- Prolyl-leucyl-glycine-amide
 - oxotremorine antagonism, 417
- Propranolol
 - autonomic blockade and heart rate conditioning, 493
- Prostaglandin, E,
 - intracranial injection and eating, 421
- Protein synthesis
 - leucine incorporation in brain cells, 573
- Puromycin
 - rat brain acetylcholinesterase inhibition, 271
- Quinterenol
 - beta-adrenergic dipsogenesis, 401, 403
- Rage
 - hypothalamic carbachol and hippocampal drugs, 285
 - intracerebral carbachol, 141
- Raphe nuclei
 - lesions, biochemical and behavioral effects, 277
 - lesion, brain 5-HT, 277
 - lesions, LSD and startle response, 675
 - lesions, morphine analgesia, 215
 - lesions, telencephalic 5-HT, 215
 - lesions, two-way avoidance, 215
 - lesions, water consumption, 215
- Red nucleus
 - carbachol and rage, 141
- REM sleep
 - amygdala pO_2 , psychotropic drugs, 763
 - deprivation, flower pot technique, 553
- Renin
 - drinking, Sar¹-Ala⁸ angiotensin II, 401
 - intracranial infusion and drinking, 509
- Reserpine
 - acoustic startle and 5-HT, 161
 - cocaine self-administration, 563
- Response force
 - chlordiazepoxide and extinction, 155
 - chlorpromazine and extinction, 155
- Retrograde amnesia
 - prolonged alcohol consumption, 63
 - sodium pentobarbital, reversal, 603
- RNA
 - uridine incorporation and learning, 579
- Ro 4-4602
 - sexual behavior, male rat, 257
- Salbutamol
 - beta-adrenergic dipsogenesis, 413
- Salt intake
 - mineralocorticoid injection, 19
- Sar¹, Ala³, Ile⁶ - angiotensin I
 - antagonism of angiotensin II drinking, 597

- Sar¹ - Ala⁸ angiotensin II
 - angiotensin II dipsogenesis, 401
 - renin dipsogenesis, 401
- Satiety
 - glucocorticoid injection, 19
- Scopolamine
 - ECS amnesia, 443
 - epinephrine and avoidance learning, 427
 - hippocampal lesions and alternation, 297
- Scopolamine hydrobromide
 - aversive threshold, rat, 631
- Scopolamine methylbromide
 - aversive threshold, rat, 631
- Scotophobin
 - behavioral effects, mouse, 147
 - stimulus specificity, 147
- Self-administration
 - alcohol and water deprivation, 447
 - apomorphine, pimozone disruption, 387
 - cocaine, suppression by punishment, 199
- Septum
 - angiotensin II and drinking, 235, 597
 - carbachol and rage, 141
 - conditioned stimulus and heart rate, 493
 - norepinephrine and drinking, 235
 - renin- and angiotensin-induced drinking, 509
- Seryl-trihydroxybenzyl-hydrazine
 - pontile lesions and grooming, 355
- Sexual behavior
 - apomorphine, 257
 - L-DOPA and Ro 4-4602, 257
 - haloperidol, 257
 - tetrabenazine, ovariectomy and adrenalectomy, 685
- Sherry
 - effect on avoidance learning, 317
- Shock avoidance
 - alcohol and retention, 63
- Sleep
 - deprivation amnesia, PCPA enhancement, 817
 - intraventricular 6-OHDA, 651
 - loxapine, paradoxical sleep, 747
 - REM sleep, flower pot technique, 553
- Startle response
 - LSD, habituation and sensitization, 675
- Sodium appetite
 - cyclophosphamide, 627
- Sodium nitrite
 - aggression, 267
- Sodium pentobarbital
 - retrograde amnesia reversal, 603
 - withdrawal and extinction, 331
- Spatial alternation
 - hippocampal lesions and atropine, 297
 - hippocampal lesions and scopolamine, 297
- Spiroperidol
 - LH self-stimulation, 735
 - striatal lesions, 181
- Spontaneous hypertension
 - 6-OHDA sympathectomy and activity, 381
- Stereotyped behavior
 - amphetamine isomers, 115
 - d-amphetamine long-term administration, 249
- Stimulus specificity
 - scotophobin, 147
- Stress
 - alcohol self selection, 27
 - plasma catecholamines, human, 757
 - plasma dopamine-beta-hydroxylase, human, 757
 - plasma renin, human, 757
- Striatum
 - lesions, activity, 697
 - lesions, amphetamine locomotion, 697
 - lesions, apomorphine effects, 181
 - lesions, spiroperidol effects, 181
- Sympathectomy
 - 6-OHDA injection, activity, 381
- Substantia nigra
 - 6-OHDA lesions and instrumental responding, 87
- Taste
 - aversion, cannabinoids, 725
- Taste aversion
 - d- vs l-amphetamine, 325
- Testosterone propionate
 - cyproterone acetate and growth, 309
- Tetrabenazine
 - ovariectomy, adrenalectomy and sexual behavior, 685
- Tetraethyl lead
 - discrimination learning, 473
 - emotional, 473
- Δ^8 -THC
 - anticonvulsant activity, 227
 - conditioned taste aversion, 725
 - tone frequency and preference, human, 607
- Δ^9 -THC
 - anticonvulsant activity, 227
 - behavioral tolerance and prior training, 243
 - conditioned taste aversion, 725
 - lever pressing acquisition and extinction, 487
 - wheel running behavior, 435
- Thalamus
 - carbachol and rage, 141
- Tolerance
 - d-amphetamine, motor activity and stereotypy, 249
 - barbital-induced drinking, 431
 - chronic methamphetamine intoxication, 503
- Tonal preference
 - human, Δ^8 -THC, 607
- Tonic immobility
 - chlorpromazine, 119
- TRH
 - L-DOPA, 5HTP and behavior, 105
- Tridione
 - photoically evoked after-discharge bursting, 839
- Tryptophan
 - brain amine levels and competitive behavior, 55
- Uridine
 - incorporation into RNA and learning, 579
- Ventral tegmental area of Tsai
 - 6-OHDA injection, avoidance and ingestive behavior, 639
- Ventricular infusion
 - amphetamine and behavioral activity, 79
 - norepinephrine and behavioral activity, 79
- Visual cortex
 - leucine incorporation and learning, 573
- Vision
 - discrimination learning, d-amphetamine, 557
 - evoked potentials and pharmacological arousal, 187
- VMH
 - insulin injection and eating, 223
- Water deprivation
 - alcohol self-administration, 447
- Water intake
 - raphe lesions, 215
- Watertight swivel
 - 2 channel, i.v. and intragastric, 131
- Withdrawal
 - alcohol dependence and consumption, 523
 - alcohol dependence and motor control, 791
 - alcohol, operant behavior, 847
 - alcohol, seizures, 835
 - pentobarbital and extinction, 331
 - morphine, saccharin aversion, 613

AUTHOR INDEX

- AHLENIUS, S., 847
 ALBERT, D. J., 443
 ALEXANDER, W. D., 557
 ALLWEIS, C., 9
 ALVES, M. R., 747
 AMIT, Z., 725
 ANDERSON, W. W., 447
 ANISMAN, H., 27, 427
 ARMSTRONG, S., 811
 ATKINSON, C. A., 831
 AVERY, D. D., 473
- BABBINI, M., 803
 BABINGTON, R. G., 127
 BAKER, T. B., 831
 BARRETT, R. J., 783
 BAXTER, B. L., 387
 BEATTY, W. W., 309
 BECKWITH, B. E., 557
 BERMAN, R. F., 831
 BIGLER, E. D., 839
 BILLIET, M., 317
 BLACK, S. L., 515
 BLOCK, M. L., 233
 BOGGAN, W. O., 97
 BOLOTOW, I., 725
 BOOTH, D. A., 481
 BOSE, W. B., 443
 BOSIN, T. R., 843
 BOTWINICK, C. Y., 375
 BREESE, G. R., 537, 639, 651
 BROPHY, P. D., 509
 BRUS, R., 719
 BURKE, L. P., 459
- CAIRNCROSS, K. D., 347
 CANNON, D. S., 831
 CARDER, B., 241, 777
 CAREY, R. J., 191, 325
 CARLINI, E. A., 55
 CARMONA, A., 531
 CHERMERINSKI, E., 317
 CHUTE, D. L., 603
 CLARK, S., 367
 COLE, B. T., 123
 COOPER, B. R., 639
 CORCORAN, M. E., 225, 725
 COVIAN, M. R., 597
 CREEL, D. J., 185
 CROSS, H. A., 473
 CROY, D. J., 545
 CUNNINGHAM, T. A., 817
 CZERESNIA, S., 55
- DALGLISH, F. W., 45
 DAMSTRA-ENTINGH, T., 73, 579
 D'ANDREA, R., 549
 DAVIS, M., 675, 827
 DAVIS, W. M., 803
 DECSI, L., 141, 285
 DEL FIACCO, M., 255
 DELMUTTI, E. E., 747
 DICARA, L. V., 19
 DOMINO, E. F., 67
 DRUCKER-COLIN, R. R., 817
- EDSON, P. H., 119
 EDWARDS, S. B., 111
 ENGEL, J., 847
 ENTINGH, D., 73, 579
 EUBANKS, E. E., 137
- FAHRNEY, D., 269
 FALK, J. L., 401, 413, 791, 835
 FECHTER, L. D., 159
 FEDER, H. H., 685
 FERRARO, D. P., 487
 FIBIGER, H. C., 87
 FINK, M., 663
 FISCHMAN, M. W., 503
 FLANDERA, V., 729
 FLEMING, D. E., 185, 839
 FOWLER, S. C., 153
 FOX, K. A., 207
 FRATTA, W., 255
 FREDERICK, G., 553
 FREDERICKS, A., 493
 FRIED, P. A., 435
 FROHMAN, L. A., 309
- GALLUP, G. G., JR., 119
 GELLER, I., 545
 GENTIL, C. G., 597
 GERALD, M. C., 557
 GESSA, G. L., 255
 GEYER, M. A., 79
 GLASSMAN, E., 73
 GLICKMAN, S. E., 233
 GLUCK, J. P., 487
 GLUCKMAN, M. I., 387
 GOLDMAN, H., 557
 GOMITA, Y., 703
 GOODALL, E. B., 191, 325
 GRABOWSKA, M., 261
 GRAEFF, F. G., 597
 GRANT, L. D., 639
 GRIFFITHS, D., 439
 GRIFFITHS, R. R., 331
 GROSSMAN, S. P., 97, 697
 GROVE, R. N., 35, 197
 GRUENER, N., 265
 GUSEL, W. A., 1
 GUTHRIE, R. D., 553
 GUTMAN, A., 259
 GUTWEIN, B. M., 753
- HARIK, S. I., 115
 HARRISON, S. D., JR., 843
 HATFIELD, J. S., 221
 HERMAN, Z. S., 719
 HERNDON, G. B., 487
 HICKS, L. E., 119
 HIGUCHI, Y., 619
 HINRICHSEN, J. J., 293
 HIRSCHHORN, I. D., 361
 HO, B. T., 669
 HO, G. K., 455
 HOUSER, V. P., 631
 HOWARD, J. L., 537, 639, 651
 HUANG, J. T., 669
 HUIDOBRO-TORO, J. P., 105
- HUNTER, B. E., 63, 523
- IZQUIERDO, J. A., 317
- JACOBS, B. L., 137
 JAQUES, L. B., 817
- KARNIOL, I. G., 607
 KARR, G. W., 367
 KASTIN, A. J., 417, 663, 693
 KATAHN, M., 293
 KELLY, P. H., 735
 KING, M. G., 347
 KING, W. T., 803
 KOBILER, D., 9
 KOMISARUK, B. R., 685
 KOSTMAN, F., 719
 KOSTOWSKI, W., 275
 KRAKOWIAK, M., 747
 KRAMER, S. Z., 459
 KRUG, M., 715
 KUCHARCZYK, J., 515
 KURIBARA, H., 619
 KURTZ, P., 259
- LARSSON, K., 685
 LEVENSON, R. W., 293
 LEVITT, R. A., 509
 LONGO, V. G., 105, 769
 LORENS, S. A., 213
- MCCALLISTER, C., 79
 MCCAUGHNAN, J. A., JR., 225, 725
 MCCOLLUM, G. C., 603
 MCEWEN, B. S., 753
 MCLAIN, W. C., III, 123
 MACCANNEL, K. L., 367
 MAH, C. J., 443
 MAICKEL, R. P., 431, 843
 MALIN, D. H., 145
 MALONEY, G. J., 431
 MANDELL, A. J., 247
 MARFAING-JALLAT, P., 131
 MARTIN, G. E., 393
 MASER, J. D., 119
 MASSOTTI, M., 769
 MASUR, J., 55
 MATTHIES, H., 573, 715
 MEILE, M. J., 131
 MEISCH, R. A., 589
 MENDELSON, W. B., 553
 MERLO, A. B., 317
 METCALF, F. U., 493
 MICHALUK, J., 261
 MILLARD, W. J., 221
 MILLER, L. H., 663
 MILLWARD, D. K., 757
 MILSTEIN, S. L., 367
 MINCH, E., 381
 MITCHELL, D., 627
 MOGENSEN, G. J., 515
 MOLTZ, H., 455
 MONTI, J. M., 763
 MOORE, J. W., 493
 MOSS, D. E., 269

MOSS, D. R., 269
MUELLER, R. A., 537, 757
MYERS, R. D., 393

NAGY, J., 285
NEILL, D. B., 97, 697
NICOLAIDIS, S., 131
NORTH, R. B., 115
NOVAKOVA, V., 729

OKUIZUMI, K., 619
OLSON, J., 241
OTT, T., 715
OVERSTREET, D. H., 45

PALFAI, T., 259
PAPPAS, B. A., 381
PARKER, L. F., 613, 627
PERES, V. L., 597
PESEZ, A., 131
PETERS, D. A. V., 381
PHILLIPS, A. G., 87
PLOTNIKOFF, N. P., 417, 693
POHLE, W., 573
PONG, S. F., 803
POWELL, D. A., 123
PROCOPIO, G. F., 191

QUADAGNO, D., 455
QUARTERMAIN, D., 375, 753
QUINTON, E. E., 171, 585

RADOW, B. L., 613
RANDALL, W., 355
REMINGTON, G., 427
REVLAND, P. B., 309
RILEY, J. N., 523
ROLLS, E. T., 735
ROSECRANS, J. A., 67, 361
ROSS, J. F., 697
ROWLAND, N., 131
RUSSELL, R. W., 45
RYBACK, R. S., 545

SAARI, M., 381
SAMSON, H. H., 791, 835
SANDERS-BUSH, E., 783
SANDMAN, C. A., 557, 663
SANDRITTER, W., 729
SBORDONE, R. J., 777
SCERNI, R. A., 387
SCHAEFER, G. J., 783
SCHALLY, A. V., 693
SCHMIDEK, M., 747
SCHMIDEK, W. R., 747
SCHMITT, M., 715
SCHNEIDER, C. W., 549
SCHNEIDERMAN, N., 493
SCHRIEBER, R., 123
SCHROEDER, T., 473
SCHUSTER, C. R., 197, 503, 563
SCHWABER, J. S., 493
SCOTTI DE CAROLIS, A., 105, 769
SEGAL, D. S., 79, 247
SHALNA, E. J., 111
SHAW, S. G., 735
SHEARD, M. H., 675, 827
SHEARER, D. E., 185, 839
SIMPSON, C. W., 19
SIMSON, P. C., 481
SINCLAIR, J. D., 409
SINGER, G., 811
SKITNEVSKY, H., 55
SLANGEN, J., 531
SMITH, C. J. V., 221
SMITH, R. D., 537, 639
SNYDER, S. H., 115
SOBRIAN, S. K., 381
SOUZA, M. R. C., 607
STEIN, L., 387
SYME, G. J., 851
SYME, L. A., 851

TADOKORO, S., 619
TAGLIAMONTE, A., 255
TANG, M., 401, 413
THOMPSON, D. M., 741

THOMPSON, T., 35, 331, 447, 589
TIMO-IARIA, C., 747
TRULSON, M., 355
TRZIL, P., 549

UEKI, S., 703

VALLIER, G. H., 233
VALZELLI, L., 275
VAN HART, D. A., 631
VAN VEEN, W. J., 663
VASQUEZ, B. J., 45
VEALE, W. L., 421
VELLUTI, R., 763
VENTURA, D. F., 607
VILBERG, T. R., 309
VORHEES, C. V., 783

WADA, J. A., 225
WAHLSTEN, D., 439
WALLER, T. G., 27
WALKER, D. W., 63, 523
WASZAK, M., 339
WEBSTER, J. C., 207
WEDEKING, P. W., 127, 465
WHISHAW, I. Q., 421
WHITE, C. L., 803
WHITE, S. R., 297
WILSON, C. E., 839
WILSON, J. E., 73
WILSON, M. C., 563
WOLF, G., 19
WOLFARTH, S., 179
WOODS, J. W., 757
WOODS, S. C., 627
WRIGHT, D. C., 603
WYATT, R. J., 553

YOSHIMURA, H., 703
YUNGER, L. M., 213

ZENICK, H., 709
ZIS, A. P., 87

